The U.S. Food and Drug Administration (FDA) has granted GW Pharmaceuticals Plc's experimental cannabis-derived epilepsy drug "orphan" status for a third group of patients affected by a rare form of the disease.

GW said on Thursday that its drug, Epidiolex, had been granted the status for the treatment of tuberous sclerosis complex (TSC), a rare genetic disorder that causes epilepsy in about 80 percent to 90 percent of the patients afflicted with it.

TSC is the third orphan indication that GW is targeting within its Epidiolex clinical development program.

Orphan status is granted to drugs aimed at treating rare diseases, giving the developer incentives such as a seven-year marketing exclusivity in the United States.

Click here to read the rest of the article

Reuters ~

Recent News Articles

Monday May 20

State Treasurers Group Endorses Marijuana Banking Legislation - Cannabis News

in Politics

by Bruce Kennedy - Editor in Chief

A group representing state treasurers and finance officials is formally calling on Congress to pass…

741 hits

Monday May 20

At Vt. Cannabis And Hemp Convention, Some Businesses Having #FOMO - Cannabis News

in Finance

by Bruce Kennedy - Editor in Chief

The Vermont Cannabis and Hemp Convention took place at the Champlain Valley Expo this weekend.

779 hits

Monday May 20

Arizona Farmers Can Begin Growing Hemp in June - Cannabis News

in Cannabis News

by Bruce Kennedy - Editor in Chief

Arizona farmers can begin planting hemp in early June. Hemp industry applications are due by…

1691 hits

Monday May 20

Cannabis-brewed Beer Prepares to Enter the New Canadian Market - Cannabis News

in World News

by Bruce Kennedy - Editor in Chief

The world’s first beer brewed from cannabis will be ready when Canada legalizes cannabis beverages…

1254 hits

Tuesday May 21

Poll: Most of Illinois says marijuana should be legal - Cannabis News

in Politics

by Bruce Kennedy - Editor in Chief

A new poll by Global Strategy Group on behalf of Think Big Illinois, says a…

924 hits